The DNA Methylation Inhibitor Zebularine Controls CD4+ T Cell Mediated Intraocular Inflammation

Yanli Zou,Xiao Hu,Lauren P. Schewitz-Bowers,Madeleine Stimpson,Li Miao,Xiaofei Ge,Liu Yang,Yan Li,Paul W. Bible,Xiaofeng Wen,Jing Jing Li,Yizhi Liu,Richard W. J. Lee,Lai Wei
DOI: https://doi.org/10.3389/fimmu.2019.01950
IF: 7.3
2019-08-16
Frontiers in Immunology
Abstract:CD4<sup>+</sup> T cell mediated uveitis is conventionally treated with systemic immunosuppressive agents, including corticosteroids and biologics targeting key inflammatory cytokines. However, their long-term utility is limited due to various side effects. Here, we investigated whether DNA methylation inhibitor zebularine can target CD4<sup>+</sup> T cells and control intraocular inflammation. Our results showed that zebularine restrained the expression of inflammatory cytokines IFN-γ and IL-17 in both human and murine CD4<sup>+</sup> T cells <i>in vitro</i>. Importantly, it also significantly alleviated intraocular inflammation and retinal tissue damage in the murine experimental autoimmune uveitis (EAU) model <i>in vivo</i>, suggesting that the DNA methylation inhibitor zebularine is a candidate new therapeutic agent for uveitis.
immunology
What problem does this paper attempt to address?